NO308742B1 - Morfolintachykininreseptorantagonister og farmasøytisk preparat inneholdende disse - Google Patents
Morfolintachykininreseptorantagonister og farmasøytisk preparat inneholdende disseInfo
- Publication number
- NO308742B1 NO308742B1 NO962523A NO962523A NO308742B1 NO 308742 B1 NO308742 B1 NO 308742B1 NO 962523 A NO962523 A NO 962523A NO 962523 A NO962523 A NO 962523A NO 308742 B1 NO308742 B1 NO 308742B1
- Authority
- NO
- Norway
- Prior art keywords
- substituted
- receptor antagonists
- tachykinin receptor
- group
- pharmaceutical preparations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16988993A | 1993-12-17 | 1993-12-17 | |
PCT/US1994/014497 WO1995016679A1 (en) | 1993-12-17 | 1994-12-13 | Morpholine and thiomorpholine tachykinin receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
NO962523D0 NO962523D0 (no) | 1996-06-14 |
NO962523L NO962523L (no) | 1996-08-16 |
NO308742B1 true NO308742B1 (no) | 2000-10-23 |
Family
ID=22617632
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO962523A NO308742B1 (no) | 1993-12-17 | 1996-06-14 | Morfolintachykininreseptorantagonister og farmasøytisk preparat inneholdende disse |
NO2004003C NO2004003I2 (no) | 1993-12-17 | 2004-04-21 | Aprepitant, eventuelt i form av et farmasøytisk akseptabelt salt |
NO2018011C NO2018011I2 (no) | 1993-12-17 | 2018-04-04 | Aprepitant, eventuelt i form av et farmasøytisk akseptabelt salt - forlenget SPC |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2004003C NO2004003I2 (no) | 1993-12-17 | 2004-04-21 | Aprepitant, eventuelt i form av et farmasøytisk akseptabelt salt |
NO2018011C NO2018011I2 (no) | 1993-12-17 | 2018-04-04 | Aprepitant, eventuelt i form av et farmasøytisk akseptabelt salt - forlenget SPC |
Country Status (41)
Country | Link |
---|---|
EP (1) | EP0734381B1 (xx) |
JP (1) | JP3245424B2 (xx) |
KR (1) | KR100335704B1 (xx) |
CN (1) | CN1057296C (xx) |
AT (1) | ATE194336T1 (xx) |
AU (1) | AU701862B2 (xx) |
BG (1) | BG64775B1 (xx) |
BR (1) | BR9408351A (xx) |
CA (1) | CA2178949C (xx) |
CO (1) | CO4340628A1 (xx) |
CY (2) | CY2203B1 (xx) |
CZ (1) | CZ295381B6 (xx) |
DE (2) | DE69425161T2 (xx) |
DK (1) | DK0734381T3 (xx) |
ES (1) | ES2147840T3 (xx) |
FI (1) | FI109532B (xx) |
FR (1) | FR04C0010I2 (xx) |
GR (1) | GR3034095T3 (xx) |
HK (1) | HK1009046A1 (xx) |
HR (1) | HRP941000B9 (xx) |
HU (1) | HU224014B1 (xx) |
IL (1) | IL111960A (xx) |
LT (1) | LTC0734381I2 (xx) |
LU (1) | LU91069I9 (xx) |
LV (1) | LV11617B (xx) |
MY (1) | MY115164A (xx) |
NL (1) | NL300146I2 (xx) |
NO (3) | NO308742B1 (xx) |
NZ (1) | NZ278222A (xx) |
PL (1) | PL182521B1 (xx) |
PT (1) | PT734381E (xx) |
RO (1) | RO118203B1 (xx) |
RU (1) | RU2201924C2 (xx) |
SA (1) | SA95150523B1 (xx) |
SI (1) | SI0734381T1 (xx) |
SK (1) | SK282800B6 (xx) |
TW (1) | TW419471B (xx) |
UA (1) | UA47397C2 (xx) |
WO (1) | WO1995016679A1 (xx) |
YU (1) | YU49037B (xx) |
ZA (1) | ZA9410008B (xx) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9408442A (pt) * | 1993-12-29 | 1997-08-05 | Merck Sharp & Dohme | Composto composição farmacêutica processos para tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquiquininas e para a preparação do composto e de uso do composto |
IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
AU690682B2 (en) * | 1994-05-05 | 1998-04-30 | Merck Sharp & Dohme Limited | Morpholine derivatives and their use as antagonists of tachikinins |
ES2157337T3 (es) * | 1994-08-15 | 2001-08-16 | Merck Sharp & Dohme | Derivados de morfolina y su uso como agentes terapeuticos. |
GB9417956D0 (en) * | 1994-09-02 | 1994-10-26 | Merck Sharp & Dohme | Therapeutic agents |
GB9505491D0 (en) * | 1995-03-18 | 1995-05-03 | Merck Sharp & Dohme | Therapeutic agents |
GB9511031D0 (en) * | 1995-06-01 | 1995-07-26 | Merck Sharp & Dohme | Chemical process |
GB9513118D0 (en) * | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
GB9523244D0 (en) * | 1995-11-14 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
US5750549A (en) * | 1996-10-15 | 1998-05-12 | Merck & Co., Inc. | Cycloalkyl tachykinin receptor antagonists |
TR199903299T2 (xx) * | 1997-07-02 | 2000-07-21 | Merck & Co., Inc. | Ta�ikinin resept�r antagonisti 2-(R)-(1-(R)- (3,5-Bis(triflorometil) Fenil)Etoksi-3-(S)- (4-Floro)Fenil-4- (3-5(-okso-1H,4H-1,2,4-Triazolo) metilmorfolin'in polimorfik formu. |
ZA985765B (en) | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
GB9813025D0 (en) | 1998-06-16 | 1998-08-12 | Merck Sharp & Dohme | Chemical synthesis |
PT1035115E (pt) | 1999-02-24 | 2005-01-31 | Hoffmann La Roche | Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1 |
CZ20013047A3 (cs) | 1999-02-24 | 2002-02-13 | F. Hoffmann-La Roche Ag | 3-Fenylpyridinové deriváty a jejich pouľití jako antagonisty NK-1 receptorů |
ES2272264T3 (es) | 1999-02-24 | 2007-05-01 | F. Hoffmann-La Roche Ag | Derivados de fenilo y piridinilo como antagonistas de neuroquinina 1. |
US6291465B1 (en) | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
ES2208205T3 (es) * | 1999-11-29 | 2004-06-16 | F. Hoffmann-La Roche Ag | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida. |
US6452001B2 (en) | 2000-05-25 | 2002-09-17 | Hoffmann-La Roche Inc. | Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation |
AR030284A1 (es) | 2000-06-08 | 2003-08-20 | Merck & Co Inc | Proceso para la sintesis de (2r, 2-alfa-r,3a) -2-[1-(3,5-bis(trifluorometil) fenil) etoxi]-3-(4-fluorofenil)-1,4-oxazina; dicho compuesto y sus formas polimorficas |
US6482829B2 (en) | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
SI1303490T1 (sl) | 2000-07-14 | 2008-10-31 | Hoffmann La Roche | N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov |
TWI287003B (en) | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
YU39503A (sh) | 2000-11-22 | 2006-05-25 | F. Hoffmann-La Roche Ag. | Derivati pirimidina |
US6642226B2 (en) | 2001-02-06 | 2003-11-04 | Hoffman-La Roche Inc. | Substituted phenyl-piperidine methanone compounds |
CA2447329C (en) * | 2001-05-14 | 2009-07-28 | F.Hoffmann-La Roche Ag | 1-oxa-3,9-diaza-spiro[5,5]undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor |
US6849624B2 (en) | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
UA76810C2 (uk) * | 2001-12-10 | 2006-09-15 | Мерк Енд Ко., Інк. | Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок |
AR039625A1 (es) * | 2002-04-18 | 2005-03-02 | Merck & Co Inc | Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona |
BRPI0406702A (pt) | 2003-01-31 | 2005-12-20 | Hoffmann La Roche | Modificação cristalina de 2-(3,5-bis-trifluormetil-fenil)-n-[6-(1,1-dioxo-1 lâmboa^6^-tiomorfolin-4-il)-4-(4-flúor-2-metil-fenil)-pi ridin-3-il]-n-metil-isobutiramida |
GB0310881D0 (en) * | 2003-05-12 | 2003-06-18 | Merck Sharp & Dohme | Pharmaceutical formulation |
ES2291891T3 (es) | 2003-07-03 | 2008-03-01 | F. Hoffmann-La Roche Ag | Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia. |
TWI280239B (en) | 2003-07-15 | 2007-05-01 | Hoffmann La Roche | Process for preparation of pyridine derivatives |
ES2246687B2 (es) | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales. |
AU2005274927B2 (en) | 2004-07-15 | 2011-11-03 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
CN101128429B (zh) | 2005-02-22 | 2012-03-21 | 弗·哈夫曼-拉罗切有限公司 | Nk1拮抗物 |
CN101146775B (zh) | 2005-03-23 | 2012-07-18 | 弗·哈夫曼-拉罗切有限公司 | 用于呕吐的用作nk-i拮抗剂的代谢物 |
ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
EP1904069B1 (en) | 2005-07-15 | 2018-06-13 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
MY143784A (en) | 2005-09-23 | 2011-07-15 | Hoffmann La Roche | Novel dosage formulation |
RU2008116844A (ru) | 2005-09-29 | 2009-11-10 | Мерк энд Ко., Инк. (US) | Ацилированные производные спиропиперидина как модуляторы рецептора меланокортина-4 |
EP1942734A4 (en) | 2005-10-06 | 2010-04-07 | Reddys Lab Ltd Dr | PREPARATION OF THE APREPITANT |
EP1984359A1 (en) * | 2006-02-03 | 2008-10-29 | Glenmark Pharmaceuticals Limited | Amorphous and crystalline forms of aprepitant and processes for the preparation thereof |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP2057151A4 (en) * | 2006-08-28 | 2010-07-21 | Hetero Drugs Ltd | PROCESS FOR PURIFYING APREPITANT |
EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
CN101190330A (zh) | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
RS58936B1 (sr) | 2007-01-10 | 2019-08-30 | Msd Italia Srl | Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp) |
JP2010516734A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | 3,5−ジアミノ−6−(2,3−ジクロロフェニル)−1,2,4−トリアジンまたはr(−)−2,4−ジアミノ−5−(2,3−ジクロロフェニル)−6−フルオロメチルピリミジンを含む医薬組成物 |
US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
BRPI0810402A2 (pt) | 2007-04-20 | 2014-11-04 | Hoffmann La Roche | Derivados de pirrolidina como antagonistas duais dos receptores nk1/nk3 |
JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体 |
ES2367464T3 (es) | 2007-08-07 | 2011-11-03 | F. Hoffmann-La Roche Ag | Pirrolidina-aril-éteres como antagonistas de receptor de nk3. |
WO2009104080A2 (en) | 2008-02-20 | 2009-08-27 | Targia Pharmaceuticals | Cns pharmaceutical compositions and methods of use |
KR20100126467A (ko) | 2008-03-03 | 2010-12-01 | 타이거 파마테크 | 티로신 키나아제 억제제 |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
SG194404A1 (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
US8716262B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
CN102595902B (zh) | 2009-05-12 | 2015-04-29 | 阿尔巴尼分子研究公司 | 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途 |
AU2010247735B2 (en) | 2009-05-12 | 2015-07-16 | Albany Molecular Research, Inc. | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof |
ES2446971T3 (es) | 2009-05-12 | 2014-03-11 | Albany Molecular Research, Inc. | Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso |
MX2012004377A (es) | 2009-10-14 | 2012-06-01 | Merck Sharp & Dohme | Piperidinas sustituidas que aumentan la actividad de p53 y sus usos. |
CN104017020B (zh) | 2010-03-31 | 2017-04-12 | 吉利德制药有限责任公司 | 核苷氨基磷酸酯 |
US8487102B2 (en) | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
ES2376564B1 (es) | 2010-08-12 | 2013-01-24 | Manuel Vicente Salinas Martín | Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer. |
CN108676800B (zh) | 2010-08-17 | 2022-11-11 | 瑟纳治疗公司 | 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制 |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
AR083095A1 (es) | 2010-09-23 | 2013-01-30 | Nuformix Ltd | Cocristal de aprepitant l-prolina y composicion farmaceutica |
EP3327125B1 (en) | 2010-10-29 | 2020-08-05 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
CN103732592A (zh) | 2011-04-21 | 2014-04-16 | 默沙东公司 | 胰岛素样生长因子-1受体抑制剂 |
WO2012146692A1 (en) | 2011-04-29 | 2012-11-01 | Sandoz Ag | Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
CN108640910A (zh) | 2011-11-25 | 2018-10-12 | 诺弗米克斯技术有限公司 | 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体 |
WO2013087964A1 (es) | 2011-12-13 | 2013-06-20 | Servicio Andaluz De Salud | Uso de agentes modificadores del ambiente peritumoral para el tratamiento del cáncer |
CZ304770B6 (cs) | 2012-03-13 | 2014-10-08 | Zentiva, K.S. | Způsob výroby 3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluormethyl)fenyl)ethoxy)-3-(4-fluorfenyl)morfolino)methyl)-1H-1,2,4-triazol-5(4H)-onu (Aprepitantu) v polymorfní formě II |
WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
EP2900241B1 (en) | 2012-09-28 | 2018-08-08 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
RU2660349C2 (ru) | 2012-11-28 | 2018-07-05 | Мерк Шарп И Доум Корп. | Композиции и способы для лечения злокачественной опухоли |
ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
ES2493693B1 (es) | 2013-02-11 | 2015-07-07 | Servicio Andaluz De Salud | Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1 |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
CN103694146B (zh) * | 2013-12-04 | 2015-10-28 | 深圳万乐药业有限公司 | 2-(2-氯-1-亚乙基)酰肼甲酸甲酯的制备方法 |
ES2541870B1 (es) | 2013-12-27 | 2016-05-12 | Servicio Andaluz De Salud | Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer |
TW201613888A (en) | 2014-09-26 | 2016-04-16 | Helsinn Healthcare Sa | Crystalline forms of an NK-1 antagonist |
US10005803B2 (en) | 2015-10-06 | 2018-06-26 | Helsinn Healthcare Sa | Crystalline forms of fosnetupitant |
LT3435980T (lt) | 2016-06-06 | 2020-02-25 | Helsinn Healthcare Sa | Fiziologiškai subalansuotos injekcinės fosnetupitanto kompozicijos |
EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
EP3833668A4 (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
US20230190740A1 (en) | 2020-04-03 | 2023-06-22 | Nerre Therapeutics Limited | An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods) |
AU2021285503A1 (en) | 2020-06-02 | 2022-12-08 | Nerre Therapeutics Limited | Neurokinin (NK)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0528495A1 (en) * | 1991-08-20 | 1993-02-24 | Merck Sharp & Dohme Ltd. | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
IL106142A (en) * | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
EP0683767B1 (en) * | 1993-02-18 | 1998-06-03 | MERCK SHARP & DOHME LTD. | Azacyclic compounds, compositions containing them and their use as tachykinin antagonists |
-
1994
- 1994-12-12 IL IL11196094A patent/IL111960A/xx active Protection Beyond IP Right Term
- 1994-12-13 NZ NZ278222A patent/NZ278222A/en not_active IP Right Cessation
- 1994-12-13 UA UA96072833A patent/UA47397C2/uk unknown
- 1994-12-13 JP JP51695995A patent/JP3245424B2/ja not_active Expired - Fee Related
- 1994-12-13 SI SI9430332T patent/SI0734381T1/xx unknown
- 1994-12-13 HU HU9601634A patent/HU224014B1/hu active Protection Beyond IP Right Term
- 1994-12-13 EP EP95905965A patent/EP0734381B1/en not_active Expired - Lifetime
- 1994-12-13 CA CA002178949A patent/CA2178949C/en not_active Expired - Lifetime
- 1994-12-13 CN CN94195008A patent/CN1057296C/zh not_active Expired - Lifetime
- 1994-12-13 RO RO96-01239A patent/RO118203B1/ro unknown
- 1994-12-13 LU LU91069C patent/LU91069I9/fr unknown
- 1994-12-13 DK DK95905965T patent/DK0734381T3/da active
- 1994-12-13 CZ CZ19961772A patent/CZ295381B6/cs not_active IP Right Cessation
- 1994-12-13 DE DE69425161T patent/DE69425161T2/de not_active Expired - Lifetime
- 1994-12-13 DE DE200412000019 patent/DE122004000019I1/de active Pending
- 1994-12-13 WO PCT/US1994/014497 patent/WO1995016679A1/en active IP Right Grant
- 1994-12-13 BR BR9408351A patent/BR9408351A/pt not_active Application Discontinuation
- 1994-12-13 AT AT95905965T patent/ATE194336T1/de active
- 1994-12-13 PT PT95905965T patent/PT734381E/pt unknown
- 1994-12-13 ES ES95905965T patent/ES2147840T3/es not_active Expired - Lifetime
- 1994-12-13 SK SK753-96A patent/SK282800B6/sk not_active IP Right Cessation
- 1994-12-13 AU AU14375/95A patent/AU701862B2/en not_active Expired
- 1994-12-13 RU RU96115181/04A patent/RU2201924C2/ru active Protection Beyond IP Right Term
- 1994-12-13 KR KR1019960703198A patent/KR100335704B1/ko not_active IP Right Cessation
- 1994-12-14 TW TW083111698A patent/TW419471B/zh not_active IP Right Cessation
- 1994-12-15 HR HRP941000AA patent/HRP941000B9/hr not_active IP Right Cessation
- 1994-12-15 ZA ZA9410008A patent/ZA9410008B/xx unknown
- 1994-12-16 MY MYPI94003369A patent/MY115164A/en unknown
- 1994-12-16 CO CO94057019A patent/CO4340628A1/es unknown
- 1994-12-16 YU YU74694A patent/YU49037B/sh unknown
-
1995
- 1995-03-14 SA SA95150523A patent/SA95150523B1/ar unknown
-
1996
- 1996-06-13 PL PL94315153A patent/PL182521B1/pl unknown
- 1996-06-14 NO NO962523A patent/NO308742B1/no not_active IP Right Cessation
- 1996-06-14 FI FI962489A patent/FI109532B/fi active Protection Beyond IP Right Term
- 1996-06-25 LV LVP-96-201A patent/LV11617B/en unknown
- 1996-07-16 BG BG100715A patent/BG64775B1/bg unknown
-
1998
- 1998-08-11 HK HK98109816A patent/HK1009046A1/xx not_active IP Right Cessation
-
2000
- 2000-08-02 GR GR20000401792T patent/GR3034095T3/el unknown
- 2000-11-24 CY CY0000056A patent/CY2203B1/xx unknown
-
2004
- 2004-04-05 NL NL300146C patent/NL300146I2/nl unknown
- 2004-04-13 FR FR04C0010C patent/FR04C0010I2/fr active Active
- 2004-04-21 NO NO2004003C patent/NO2004003I2/no unknown
- 2004-05-06 CY CY2004012C patent/CY2004012I2/el unknown
- 2004-05-07 LT LTPA2004002C patent/LTC0734381I2/lt unknown
-
2018
- 2018-04-04 NO NO2018011C patent/NO2018011I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO308742B1 (no) | Morfolintachykininreseptorantagonister og farmasøytisk preparat inneholdende disse | |
YU45293A (sh) | Morfolin i tiomorfolin tahikinin antagonisti receptora | |
NO308248B1 (no) | Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat | |
NO911525D0 (no) | Nye 2,9-disubstituerte-4h-pyrido(1,2-a)pyrimidin-4-oner. | |
NO973652D0 (no) | 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyre og derivater som tachykininreseptor-antagonist | |
DE69402703D1 (de) | 3-(INDOL-3-YL) PROPENSäURDERIVATE, DIE ALS NMDA- ANTAGONISTEN NÜTZLICH SIND | |
ATE364594T1 (de) | (4-acylaminopiperidin-1-yl)acetamide als neurokininantagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: APREPITANT, EVENTUELT I FORM AV ET FARMASOYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU103262001 NO-006 20031215; FIRST REG. NO/DATE: NO , EU103262001-006 20031113 Spc suppl protection certif: 2004003 Filing date: 20040421 Extension date: 20181113 Effective date: 20061003 |
|
MK1K | Patent expired | ||
SPCK | Change in the validity period of an spc |
Free format text: PRODUCT NAME: APREPITANT, EVENTUELT I FORM AV ET FARMASOYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU103262001 NO-006 20031215; FIRST REG. NO/DATE: NO , EU103262001-006 20031113 Spc suppl protection certif: 2004003 Filing date: 20040421 |
|
SPCE | Application to extend a supplementary protection certificate (spc) |
Free format text: PRODUCT NAME: APREPITANT, EVENTUELT I FORM AV ET FARMASOYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU/1/03/262/001-006 20031215; FIRST REG. NO/DATE: EU , EU/1/03/262/001-006 20031113 Spc suppl protection certif: 2018011 Filing date: 20180404 Extension date: 20190513 |
|
SPCX | Expiry of an spc |
Spc suppl protection certif: 2004003 Effective date: 20181113 |
|
SPCH | Extension of a supplementary protection certificate (spc) granted |
Free format text: PRODUCT NAME: APREPITANT, EVENTUELT I FORM AV ET FARMASOYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU/1/03/262/001-006 20031215; FIRST REG. NO/DATE: EU , EU/1/03/262/001-006 20031113 Spc suppl protection certif: 2018011 Filing date: 20180404 Extension date: 20190513 |
|
SPCZ | Expiry of an extension of a supplementary protection certificate (spc) |
Spc suppl protection certif: 2018011 Effective date: 20190513 |